HUP0103530A2 - N,N-szubsztituált ciklusos aminvegyületek és ezeket tartalmazó gyógyászati készítmények - Google Patents

N,N-szubsztituált ciklusos aminvegyületek és ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0103530A2
HUP0103530A2 HU0103530A HUP0103530A HUP0103530A2 HU P0103530 A2 HUP0103530 A2 HU P0103530A2 HU 0103530 A HU0103530 A HU 0103530A HU P0103530 A HUP0103530 A HU P0103530A HU P0103530 A2 HUP0103530 A2 HU P0103530A2
Authority
HU
Hungary
Prior art keywords
group
formula
brain
disease
atom
Prior art date
Application number
HU0103530A
Other languages
English (en)
Inventor
Shinji Hatakeyama
Yoichi Iimura
Koichi Ito
Koki Kawano
Teiji Kimura
Makoto Komatsu
Satoshi Nagato
Tetsuhiro Niidome
Yoshihiko Norimine
Yuichi Suzuki
Tetsuyuki Teramoto
Noboru Yamamoto
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Publication of HUP0103530A2 publication Critical patent/HUP0103530A2/hu
Publication of HUP0103530A3 publication Critical patent/HUP0103530A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A tal lm ny t rgy t (VIII) ltal nos képletű N,N-szubsztitu lt ciklusosaminvegyületek és gyógy szatilag elfogadható sóik képezik - aképletben A jelentése jellemzően egy adott esetben szubsztitu ltaril-, heteroaril-, aralkil- vagy heteroaril-alkilcsoport; E jelentéseegy -CO- vagy -CHOH- képletű csoport; G jelentése jellemzőenoxigénatom, kénatom vagy -NR10- ltal nos képletű csoport J jelentéseadott esetben szubsztitu lt aril- vagy heteroarilcsoport; R1 jelentésejellemzően hidrogénatom, halogénatom, hidroxil-, adott esetbenszubsztitu lt alkil-, alkenil-, alkinil-, cikloalkilcsoport, Alkjelentése egyenes vagy el gazó l ncú kis szénatomsz mú alkiléncsoport;n, v, w, x és y jelentése egym stól függetlenül 0 vagy 1 és pjelentése 2 vagy 3. A tal lm ny szerinti vegyületek olyan betegségekmegelőzésére, kezelésére és enyhítésére alkalmasak, melyek ellen akalciumcsatorn k g tl sa hatékony. Ezen betegségek k"zé tartoznak ak"vetkezők: akut isémi s stroke, apoplexia cerebri (agyvérzés),infarctus cerebri (agysz"vet elhal s), koponyatrauma, agyi idegsejtpusztul s, Alzheimer-kór, Parkinson-kór, amiotrofi s later lisszklerózis, Huntington-kór, agyi keringési anyagcserezavar,agyműk"désbeli zavar, f jdalom, g"rcs, skizofrénia, migrén,epilepszia, m ni kus-depresszív pszichózis, idegrendszeri degeneratívkórképek, agyi ischaemia, az AIDS demencia sz"vődményei, "déma,idegesség (generaliz lt anxietas) és diabéteszes neurop tia. Ó
HU0103530A 1998-07-21 1999-07-21 N,n-substituted cyclic amine derivatives and pharmaceutical compositions containing them HUP0103530A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20570998 1998-07-21
JP28010398 1998-10-01
PCT/JP1999/003900 WO2000005210A1 (fr) 1998-07-21 1999-07-21 Derives d'amine cyclique n,n-substitues

Publications (2)

Publication Number Publication Date
HUP0103530A2 true HUP0103530A2 (hu) 2002-04-29
HUP0103530A3 HUP0103530A3 (en) 2002-09-30

Family

ID=26515211

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103530A HUP0103530A3 (en) 1998-07-21 1999-07-21 N,n-substituted cyclic amine derivatives and pharmaceutical compositions containing them

Country Status (14)

Country Link
US (1) US6737425B1 (hu)
EP (1) EP1099692B1 (hu)
KR (1) KR100627608B1 (hu)
CN (1) CN1310709A (hu)
AT (1) ATE325097T1 (hu)
AU (1) AU758246B2 (hu)
CA (1) CA2337941A1 (hu)
DE (1) DE69931163T2 (hu)
HU (1) HUP0103530A3 (hu)
NO (1) NO318797B1 (hu)
NZ (1) NZ509310A (hu)
RU (1) RU2232156C2 (hu)
TW (1) TWI250152B (hu)
WO (1) WO2000005210A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667412B1 (en) 1999-03-16 2003-12-23 Eisai Co., Ltd. Nitrile compound
RU2230060C2 (ru) * 2000-01-20 2004-06-10 Эйсай Ко., Лтд. Соединения, фармацевтическая композиция, способ предотвращения гибели нервных клеток, способ профилактики
WO2001066534A2 (en) * 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2003207219A1 (en) 2002-02-05 2003-09-02 Ajinomoto Co., Inc. Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
CA2625687A1 (en) * 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Antibacterial active 5-chinolin derivative
KR101038053B1 (ko) * 2008-08-06 2011-05-31 임봉근 샌들바닥의 구조
CN102199122A (zh) * 2010-03-23 2011-09-28 范扶民 高哌嗪衍生物及其制备方法
US10301318B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Neuroactive compounds and methods of using the same
GB2536650A (en) 2015-03-24 2016-09-28 Augmedics Ltd Method and system for combining video-based and optic-based augmented reality in a near eye display
HUE049979T2 (hu) 2017-03-20 2020-11-30 Forma Therapeutics Inc Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként
EP3787543A4 (en) 2018-05-02 2022-01-19 Augmedics Ltd. REGISTRATION OF A REFERENCE MARK FOR AN AUGMENTED REALITY SYSTEM
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
US11766296B2 (en) 2018-11-26 2023-09-26 Augmedics Ltd. Tracking system for image-guided surgery
US11980506B2 (en) 2019-07-29 2024-05-14 Augmedics Ltd. Fiducial marker
US11382712B2 (en) 2019-12-22 2022-07-12 Augmedics Ltd. Mirroring in image guided surgery
US11896445B2 (en) 2021-07-07 2024-02-13 Augmedics Ltd. Iliac pin and adapter
CN114315802B (zh) * 2021-12-14 2023-06-16 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670478A1 (de) * 1967-10-12 1971-02-11 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des alpha-Piperazino-phenylacetonitrils
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US4886809A (en) * 1986-07-31 1989-12-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
WO1990013539A1 (en) 1989-04-28 1990-11-15 Meiji Seika Kaisha, Ltd. New n-substituted piperazine derivatives and drug for improving functional disorder of brain
EP0441226A1 (en) 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
ES2036926B1 (es) * 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
JPH0597673A (ja) * 1991-10-08 1993-04-20 Ajinomoto Co Inc 抗不整脈薬
ES2062943B1 (es) * 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6667412B1 (en) * 1999-03-16 2003-12-23 Eisai Co., Ltd. Nitrile compound

Also Published As

Publication number Publication date
TWI250152B (en) 2006-03-01
NZ509310A (en) 2003-07-25
CN1310709A (zh) 2001-08-29
EP1099692B1 (en) 2006-05-03
EP1099692A1 (en) 2001-05-16
CA2337941A1 (en) 2000-02-03
NO20010303L (no) 2001-03-21
WO2000005210A1 (fr) 2000-02-03
EP1099692A4 (en) 2002-05-15
KR20010083133A (ko) 2001-08-31
AU4798099A (en) 2000-02-14
ATE325097T1 (de) 2006-06-15
RU2232156C2 (ru) 2004-07-10
HUP0103530A3 (en) 2002-09-30
KR100627608B1 (ko) 2006-09-25
NO20010303D0 (no) 2001-01-18
NO318797B1 (no) 2005-05-09
DE69931163T2 (de) 2007-02-01
DE69931163D1 (de) 2006-06-08
AU758246B2 (en) 2003-03-20
US6737425B1 (en) 2004-05-18

Similar Documents

Publication Publication Date Title
HUP0103530A2 (hu) N,N-szubsztituált ciklusos aminvegyületek és ezeket tartalmazó gyógyászati készítmények
HUP0303808A2 (hu) Kondenzált biciklusos vagy triciklusos aminosavak, aljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
CA2177773C (fr) Nouveaux aryl(alkyl)propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ECSP066858A (es) Inhibidores de gsk-3
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
NZ510145A (en) Branched alkyl pyrrolidine-3-carboxylic acids useful in protective action against cardiazole cramp and cerebral conditions such as epilepsy, hypokinesia and cranial traumas
CY1106237T1 (el) Ετepοκυκλικα παραγωγα με 5 μελη στο δακτυλιο και εφαρμογη αυτων ως παρεμποδιστων της μονοαμινο οξυδασης
CA2471577A1 (en) Chemical compounds
BRPI0415972A (pt) derivados de diamina, processo para produção desses derivados, e agentes para controle de doenças de plantas os quais contêm esses derivados como ingredientes ativos
DOP2004000888A (es) 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes
BRPI0608032A2 (pt) composição para o cuidado do cabelo e/ou do couro cabeludo, método para tratar e/ou prevenir as afecções inflamatórias da pele, uso de um composto de amino-oxo-indol-ilideno e uso de uma composição
HUP0300080A2 (hu) Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények
NZ590951A (en) Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders
JPS55127384A (en) Novel chromone compound*its manufacture and drug composition containing it
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
FR3030240B1 (fr) Procede de traitement des fibres keratiniques avec une composition comprenant un acide amine
NO20064752L (no) N-piperidinderivater som CCR3-modulatorer
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
DE69326395T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
EP1640367A4 (en) ISOQUINOLINE-1,3,4-TRIONE, SYNTHETIC PROCESS AND USE THEREOF
HK1054373A1 (en) Vitamin d derivatives possessing a 22-oxa or 22-thia atom, a c17-side chain substituted by an acid, ester or amide group and a 16(17)-double bond
EA014959B3 (ru) Ингибиторы глицинового переносчика-1
MX2022012293A (es) Composiciones de agentes de acido ribonucleico de interferencia (arni) de la proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
BR0007784A (pt) Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: EISAI R&D MANAGEMENT CO., LTD., JP

Free format text: FORMER OWNER(S): EISAI CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees